Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,567,997
  • Shares Outstanding, K 207,133
  • Annual Sales, $ 331,410 K
  • Annual Income, $ -226,540 K
  • EBIT $ -41 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.79
  • Price/Sales 4.62
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 73.70% ( +4.15%)
  • Historical Volatility 45.06%
  • IV Percentile 69%
  • IV Rank 44.30%
  • IV High 132.06% on 02/13/24
  • IV Low 27.27% on 10/11/24
  • Put/Call Vol Ratio 0.38
  • Today's Volume 142
  • Volume Avg (30-Day) 1,023
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 48,194
  • Open Int (30-Day) 44,523

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.16
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.02 +7.83%
on 11/21/24
8.16 -7.23%
on 12/06/24
+0.27 (+3.70%)
since 11/20/24
3-Month
6.84 +10.59%
on 11/04/24
8.44 -10.31%
on 11/01/24
-0.54 (-6.66%)
since 09/20/24
52-Week
4.03 +87.84%
on 04/25/24
8.88 -14.75%
on 09/03/24
+1.93 (+34.22%)
since 12/20/23

Most Recent Stories

More News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX : 7.57 (+2.44%)
BioCryst Pharmaceuticals' ORLADEYO® Recommended for Routine Prevention of Hereditary Angioedema Attacks in Ireland

BioCryst Pharmaceuticals announces HSE recommendation for ORLADEYO® to prevent hereditary angioedema attacks in eligible patients aged 12 and older.Quiver AI SummaryBioCryst Pharmaceuticals announced...

BCRX : 7.57 (+2.44%)
BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BCRX : 7.57 (+2.44%)
BioCryst to Present at Upcoming Investor Conferences

BCRX : 7.57 (+2.44%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX : 7.57 (+2.44%)
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2024.

BCRX : 7.57 (+2.44%)
BioCryst: Q3 Earnings Snapshot

BioCryst: Q3 Earnings Snapshot

BCRX : 7.57 (+2.44%)
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BCRX : 7.57 (+2.44%)
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

BCRX : 7.57 (+2.44%)
BioCryst to Report Third Quarter 2024 Financial Results on November 4

BCRX : 7.57 (+2.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 8.05
2nd Resistance Point 7.82
1st Resistance Point 7.70
Last Price 7.57
1st Support Level 7.35
2nd Support Level 7.12
3rd Support Level 7.00

See More

52-Week High 8.88
Last Price 7.57
Fibonacci 61.8% 7.03
Fibonacci 50% 6.45
Fibonacci 38.2% 5.88
52-Week Low 4.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar